Presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma: Implications for the outcome

Jorge A. Ortega, Jon Rowland, Hector Monforte, Marcio Malogolowkin, Timothy Triche

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The presence of well-differentiated rhabdomyoblasts at the end of therapy for rhabdomyosarcoma has been noted. This study was undertaken to investigate the therapeutic implications of the presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma. Six patients with pelvic rhabdomyosarcoma (bladder-prostate, 4; vulvovaginal, 2) with disease diagnosed between the years 1974 and 1992 were sequentially investigated by cystoscopic or vaginoscopic examination and biopsy during and after completing therapy. All six patients received treatment according to prevailing therapeutic protocols. Biopsy material from all six patients at the end of therapy documented the presence of well-differentiated rhabdomyoblasts. Repeated biopsies demonstrated the presence of rhabdomyoblasts; however, they appeared to decrease in number with time. Mitotic activity was not observed in the biopsy materials obtained. All six patients are alive without evidence of disease from 37 to 233 months after therapy ended. The presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma is a common finding. The biologic nature of these well-differentiated rhabdomyoblasts is not completely known, but they do not appear to connote the persistent presence of malignant disease and are not an indication for the continuation of therapy.

Original languageEnglish (US)
Pages (from-to)106-111
Number of pages6
JournalAmerican Journal of Pediatric Hematology/Oncology
Volume22
Issue number2
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Rhabdomyosarcoma
Biopsy
Therapeutics
Prostate
Urinary Bladder

Keywords

  • Differentiated rhabdomyoblasts
  • End of therapy
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma : Implications for the outcome. / Ortega, Jorge A.; Rowland, Jon; Monforte, Hector; Malogolowkin, Marcio; Triche, Timothy.

In: American Journal of Pediatric Hematology/Oncology, Vol. 22, No. 2, 01.01.2000, p. 106-111.

Research output: Contribution to journalArticle

@article{3afe78cc6667407ab729f38693240ec3,
title = "Presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma: Implications for the outcome",
abstract = "The presence of well-differentiated rhabdomyoblasts at the end of therapy for rhabdomyosarcoma has been noted. This study was undertaken to investigate the therapeutic implications of the presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma. Six patients with pelvic rhabdomyosarcoma (bladder-prostate, 4; vulvovaginal, 2) with disease diagnosed between the years 1974 and 1992 were sequentially investigated by cystoscopic or vaginoscopic examination and biopsy during and after completing therapy. All six patients received treatment according to prevailing therapeutic protocols. Biopsy material from all six patients at the end of therapy documented the presence of well-differentiated rhabdomyoblasts. Repeated biopsies demonstrated the presence of rhabdomyoblasts; however, they appeared to decrease in number with time. Mitotic activity was not observed in the biopsy materials obtained. All six patients are alive without evidence of disease from 37 to 233 months after therapy ended. The presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma is a common finding. The biologic nature of these well-differentiated rhabdomyoblasts is not completely known, but they do not appear to connote the persistent presence of malignant disease and are not an indication for the continuation of therapy.",
keywords = "Differentiated rhabdomyoblasts, End of therapy, Rhabdomyosarcoma",
author = "Ortega, {Jorge A.} and Jon Rowland and Hector Monforte and Marcio Malogolowkin and Timothy Triche",
year = "2000",
month = "1",
day = "1",
doi = "10.1097/00043426-200003000-00005",
language = "English (US)",
volume = "22",
pages = "106--111",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma

T2 - Implications for the outcome

AU - Ortega, Jorge A.

AU - Rowland, Jon

AU - Monforte, Hector

AU - Malogolowkin, Marcio

AU - Triche, Timothy

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The presence of well-differentiated rhabdomyoblasts at the end of therapy for rhabdomyosarcoma has been noted. This study was undertaken to investigate the therapeutic implications of the presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma. Six patients with pelvic rhabdomyosarcoma (bladder-prostate, 4; vulvovaginal, 2) with disease diagnosed between the years 1974 and 1992 were sequentially investigated by cystoscopic or vaginoscopic examination and biopsy during and after completing therapy. All six patients received treatment according to prevailing therapeutic protocols. Biopsy material from all six patients at the end of therapy documented the presence of well-differentiated rhabdomyoblasts. Repeated biopsies demonstrated the presence of rhabdomyoblasts; however, they appeared to decrease in number with time. Mitotic activity was not observed in the biopsy materials obtained. All six patients are alive without evidence of disease from 37 to 233 months after therapy ended. The presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma is a common finding. The biologic nature of these well-differentiated rhabdomyoblasts is not completely known, but they do not appear to connote the persistent presence of malignant disease and are not an indication for the continuation of therapy.

AB - The presence of well-differentiated rhabdomyoblasts at the end of therapy for rhabdomyosarcoma has been noted. This study was undertaken to investigate the therapeutic implications of the presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma. Six patients with pelvic rhabdomyosarcoma (bladder-prostate, 4; vulvovaginal, 2) with disease diagnosed between the years 1974 and 1992 were sequentially investigated by cystoscopic or vaginoscopic examination and biopsy during and after completing therapy. All six patients received treatment according to prevailing therapeutic protocols. Biopsy material from all six patients at the end of therapy documented the presence of well-differentiated rhabdomyoblasts. Repeated biopsies demonstrated the presence of rhabdomyoblasts; however, they appeared to decrease in number with time. Mitotic activity was not observed in the biopsy materials obtained. All six patients are alive without evidence of disease from 37 to 233 months after therapy ended. The presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma is a common finding. The biologic nature of these well-differentiated rhabdomyoblasts is not completely known, but they do not appear to connote the persistent presence of malignant disease and are not an indication for the continuation of therapy.

KW - Differentiated rhabdomyoblasts

KW - End of therapy

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=0034458293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034458293&partnerID=8YFLogxK

U2 - 10.1097/00043426-200003000-00005

DO - 10.1097/00043426-200003000-00005

M3 - Article

C2 - 10779022

AN - SCOPUS:0034458293

VL - 22

SP - 106

EP - 111

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 2

ER -